Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLOMIPHENE CITRATE vs OSPHENA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.
Selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and lipid metabolism, and as an estrogen antagonist on breast and uterine tissue. It mimics estrogen's effects on bone by reducing bone resorption and increasing bone mineral density.
Treatment of ovulatory dysfunction in women desiring pregnancy,Off-label: male infertility (oligospermia), induction of ovulation in assisted reproductive technology
Treatment of osteoporosis in postmenopausal women at high risk of fracture,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis,Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer
50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.
60 mg orally once daily with food.
Terminal elimination half-life is approximately 5–7 days (120–168 hours) for the active zu-isomer, with a longer half-life for its metabolites. This prolonged half-life leads to accumulation with repeated dosing and sustained clinical effects.
The terminal elimination half-life of ospemifene is approximately 26 hours (range 22-39 hours), supporting once-daily dosing.
Hepatic metabolism; excreted in feces; active metabolites (possibly enterohepatic recirculation).
Extensively metabolized in the liver via glucuronidation (UGT1A8, UGT1A10, UGT2B7) and to a lesser extent by cytochrome P450 (CYP3A4, CYP2C19). Undergoes enterohepatic recycling. Half-life is approximately 5.7 days.
Primarily fecal (approximately 50%), with about 8% renal excretion of unchanged drug and metabolites. Biliary excretion is significant, with enterohepatic recirculation contributing to prolonged elimination.
Following oral administration, 50% of a radiolabeled dose is excreted in urine and 35% in feces within 168 hours, primarily as glucuronide conjugates; <1% is excreted unchanged.
Approximately 80–90% bound to albumin, with significant binding to other plasma proteins including sex hormone-binding globulin (SHBG).
Ospemifene is >99% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is large, approximately 50–100 L/kg, indicating extensive tissue distribution and accumulation, particularly in the liver and reproductive organs.
The apparent volume of distribution (Vd/F) is approximately 2.4 L/kg, indicating extensive tissue distribution.
Oral: ~100% absorbed, but bioavailability is difficult to quantify due to extensive first-pass metabolism and enterohepatic cycling; essentially complete systemic exposure after oral administration.
Absolute bioavailability is approximately 30% after oral administration due to first-pass metabolism.
No specific dose adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (Cr Cl <30 m L/min).
Contraindicated in patients with liver disease or hepatic dysfunction; no Child-Pugh based adjustments available.
Child-Pugh A: no adjustment; Child-Pugh B: not recommended; Child-Pugh C: contraindicated.
Not recommended for use in children; safety and efficacy not established.
Safety and efficacy not established; no specific dosing guidelines.
Not indicated for use in elderly patients; no specific dosing recommendations.
No specific dose adjustment; monitor for dysphagia and esophageal adverse effects.
Should not be used in patients with liver disease or abnormal uterine bleeding of undetermined origin.
Increased risk of venous thromboembolic events (including deep vein thrombosis and pulmonary embolism) and death due to stroke. Use is contraindicated in women with active or past history of venous thromboembolism.
Ovarian enlargement/cysts; visual disturbances; multiple pregnancy; ovarian hyperstimulation syndrome; vasomotor symptoms; blurred vision; prolonged use may increase risk of borderline or invasive ovarian tumors.
Increased risk of venous thromboembolic events and stroke; consider risk-benefit in women at risk for these events. May cause hot flashes and leg cramps. Use with caution in patients with hepatic impairment or history of cholestasis. Not recommended for use in premenopausal women. Discontinue if prolonged immobilization occurs. Monitor lipid profile; may cause small reductions in HDL cholesterol.
Pregnancy; liver disease or history; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement due to polycystic ovary syndrome; hypersensitivity to clomiphene.
Active or past history of venous thromboembolism (DVT, PE, retinal vein thrombosis), pregnancy (can cause fetal harm), women who are or may become pregnant, nursing mothers, patients with hypersensitivity to raloxifene or any component of the formulation.
No significant food interactions. Avoid excessive alcohol consumption as it may impair fertility.
No specific food interactions; take with food to minimize gastrointestinal side effects.
FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and third trimester: no data due to contraindication. Risk of multiple gestation (5-12%) increases risks of preterm labor, low birth weight, and congenital anomalies.
Ospemifene is contraindicated in pregnancy. Based on its mechanism as a selective estrogen receptor modulator (SERM) and animal studies showing embryotoxicity and teratogenicity, there is potential for fetal harm. First trimester exposure may increase risk of congenital anomalies; second/third trimester exposure may cause urogenital tract abnormalities and endocrine disruption.
Excreted into breast milk; M/P ratio unknown. Clomiphene may reduce milk production due to anti-estrogenic effects. Because of potential for adverse reactions in nursing infants, women are advised not to breastfeed during treatment.
No data on human milk excretion. Ospemifene may suppress lactation due to estrogenic effects. M/P ratio unknown. Avoid breastfeeding during treatment and for at least 2 weeks after last dose.
No dose adjustments in pregnancy as drug is contraindicated. If pregnancy occurs, discontinue immediately. No pharmacokinetic studies in pregnant women; drug should not be used.
No dose adjustments studied; contraindicated in pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered clearance) may occur but no data to guide dosing.
Monitor ovarian size and estradiol levels to reduce risk of ovarian hyperstimulation syndrome (OHSS). Use only in patients with ovulatory dysfunction; rule out pregnancy before each cycle. Limit to 6 treatment cycles due to increased risk of ovarian cancer with prolonged use.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy in postmenopausal women. Avoid in women with estrogen-dependent neoplasia, unexplained genital bleeding, or prior thromboembolic events. Monitor for endometrial hyperplasia because uterine stimulation can occur. Not for use in premenopausal women.
Take clomiphene citrate exactly as prescribed, typically for 5 days starting on day 3-5 of menstrual cycle.,Ovulation usually occurs 5-10 days after the last dose; have intercourse every other day during this window.,Common side effects include hot flashes, mood swings, and visual disturbances; report persistent visual changes immediately.,Risk of multiple pregnancy (mainly twins) is increased; discuss with healthcare provider.,Avoid use if pregnant, have liver disease, or have abnormal vaginal bleeding.
Take daily with food to reduce nausea.,Do not take if you have a history of blood clots, breast cancer, or uterine cancer.,Report any unusual vaginal bleeding, breast pain, or leg swelling immediately.,May cause hot flashes, vaginal discharge, or muscle spasms.,Use proper lubricants during intercourse; this medicine does not protect against STIs.,Continue regular pelvic exams and mammograms as recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLOMIPHENE CITRATE vs OSPHENA, answered by our medical review team.
CLOMIPHENE CITRATE is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.. OSPHENA is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and lipid metabolism, and as an estrogen antagonist on breast and uterine tissue. It mimics estrogen's effects on bone by reducing bone resorption and increasing bone mineral density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLOMIPHENE CITRATE and OSPHENA depend on the specific clinical indication. These are both Selective Estrogen Receptor Modulator (SERM) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLOMIPHENE CITRATE is: 50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.. The standard adult dose of OSPHENA is: 60 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLOMIPHENE CITRATE and OSPHENA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLOMIPHENE CITRATE is classified as Category A/B. FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and. OSPHENA is classified as Category C. Ospemifene is contraindicated in pregnancy. Based on its mechanism as a selective estrogen receptor modulator (SERM) and animal studies showing embryotoxicity and teratogenicity, t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.